XBI State Street SPDR S&P Biotech ETF

Mentions (16)

• News (RSS)fool·1d ago·Positive

  Better Healthcare ETF: Fidelity's Broad, Low-Cost FHLC vs. State Street's XBI Targeting Biotech Fidelity offers lower costs and steadier returns, while State Street targets smaller biotech companies with higher volatility and recent outperformance.

  View source ↗
• News (RSS)fool·2d ago·Negative

  Better State Street Healthcare ETF: XBI's Biotech Focus vs. XPH Targeting Pharmaceuticals XPH delivered 19% higher returns over five years despite half the volatility. XBI's 165 holdings offer broader exposure but with a 53% maximum drawdown.

  View source ↗
• Newsfool.com·2d ago·Neutral

  Better State Street Healthcare ETF: XBI's Biotech Focus vs. XPH Targeting Pharmaceuticals The State Street SPDR S&P Biotech ETF and State Street SPDR S&P Pharmaceuticals ETF carry identical 0.35% expense ratios. The State Street SPDR S&P Pharmaceuticals ETF has historically exhibited significantly lower price volatility and a smaller maximum drawdown than its biotech counterpart.

  View source ↗
• Newszacks.com·7d ago·Positive

  Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now? Making its debut on 01/31/2006, smart beta exchange traded fund State Street SPDR S&P Biotech ETF (XBI) provides investors broad exposure to the Health Care ETFs category of the market.

  View source ↗
• 4chan /biz/biz·13d ago·Neutral

  >>62717141 LLY runs up every once in awhile, or down every once in awhile but it keeps returning to the mean of XBI

  View source ↗
• 4chan /biz/biz·13d ago·Neutral

  Did you ever notice how closely LLY moves with XBI? There's something going on here. It can't just be a coincidence.

  View source ↗
• News (RSS)fool·13d ago·Neutral

  VHT vs. XBI: Is Diversified Healthcare Exposure or Biotech Stocks the Smarter Choice for Investors? VHT offers broad sector exposure with lower volatility, while XBI concentrates on biotech with higher risk and reward. Here's how to decide between the two.

  View source ↗
• News (RSS)zerohedge·28d ago·Neutral

  …e despite stalled payrolls... ... then it will restore credibility and make sure the current "peak yields" don't go higher, it's also why to Hartnett, duration (RTY, XBI, KRE, REIT) keeps working despite surging yields and why "nouveau-leveraged" Mag7s are on the cusp of upside breakout. On the other hand, if the Fed does not hike - as Trump made painfully clear he will not approve - or even merely keeps rates on hold, then all bets are off, as is the Fed's credibility because for all his rhetor…

  View source ↗
• News (RSS)seekingalpha·30d ago·Positive

  XBI: Big Pharma Can Keep The 76% Rally Going

  View source ↗
• Newsseekingalpha.com·30d ago·Positive

  XBI: Big Pharma Can Keep The 76% Rally Going State Street SPDR S&P Biotech ETF (XBI) is rated Buy, with 8%-14% total return expected over 6-12 months despite a 76% prior-year rally. XBI's modified equal-weight structure offers broad exposure to over 150 biotech names, benefiting from ongoing M&A and improved capital access. Recent large-cap pharma acquisitions and selective capital flows support XBI's thesis, though volatility remains high and returns are likely to moderate.

  View source ↗
• PodcastCompound And Friends·34d ago·Neutral

  …ors, but that's how we're doing here, this is not what I'm doing, so I wasn't in the name to begin with, but terrible make the case, although I did make the case for XBI, and that was a good one. But here's my next one anyway, but here's my next one, I'm doing a Josh, yeah, like me now, from my next trip, if you like those, you're gonna love this, so I bought, I bought clear yesterday, not a lot, this is a very speculative stock, the ticker is why are you, these are the things that airports that…

  View source ↗
• Newsfxempire.com·41d ago·Positive

  XBI Forecast: $174.79 Tests Biotech ETF Breakout Strength XBI approaches its 2021 high at $174.79 after a bullish flag breakout, setting up a key test between further gains and a potential consolidation.

  View source ↗
• Newszacks.com·43d ago·Neutral

  Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)? Launched on January 31, 2006, the State Street SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.

  View source ↗
• News (RSS)seekingalpha·46d ago·Positive

  XBI: Biotech's Breakthrough Moment Happend This Week (Upgrade)

  View source ↗
• Newsseekingalpha.com·46d ago·Positive

  XBI: Biotech's Breakthrough Moment Happend This Week (Upgrade) State Street SPDR S&P Biotech ETF (XBI) is upgraded to buy as bullish momentum and reasonable valuation converge amid sector-wide optimism. XBI has surged 34% since March, outperforming XLV and SPY, fueled by M&A activity and positive clinical trial catalysts. Despite high volatility and small-cap risk, XBI's under-20x earnings multiple and diversified holdings support a constructive outlook.

  View source ↗
• News (RSS)fool·48d ago·Positive

  Which Healthcare ETF Is the Better Buy: VanEck's Pharma PPH or State Street's Biotech XBI? PPH offers the income and stability of proven pharmaceutical leaders while XBI swings for the fences across 155 smaller biotech names.

  View source ↗